CardiNor AS and its partners Bioventix Ltd, Kaivogen Oy and Akershus University hospital have been granted Eurostars funding of the project: Secretoneurin, a breakthrough blood biomarker for heart disease and Sudden Cardiac Arrest risk. The total funding by EU is € 631,000. The Eurostars project will support the following important milestones for the company: Development and optimization of a simple test for measuring SN in the blood – Clinical validation using a very comprehensive patient material, this will also support and facilitate future CE marking – Optimization of assay production that will enable rapid commercialization.
In the media
Unicard, 17.11.2016: (secretoneurin predicts mortality in patients with acute respiratory failure. Article in Norwegian)
Scientific Nordic, 02.10.2015: